Natural Course of Nonsevere Secondary Tricuspid Regurgitation.

Effective regurgitant orifice area Heart failure with reduced ejection fraction Progressive tricuspid regurgitation Regurgitant volume Secondary tricuspid regurgitation

Journal

Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
ISSN: 1097-6795
Titre abrégé: J Am Soc Echocardiogr
Pays: United States
ID NLM: 8801388

Informations de publication

Date de publication:
01 2021
Historique:
received: 04 02 2020
revised: 17 08 2020
accepted: 17 08 2020
pubmed: 11 10 2020
medline: 25 9 2021
entrez: 10 10 2020
Statut: ppublish

Résumé

Secondary tricuspid regurgitation (sTR) is frequent in patients with heart failure with reduced ejection fraction and is associated with adverse outcomes despite guideline-directed therapy. However, little is known about the natural course of nonsevere sTR and its relation to cardiac remodeling and outcomes. The aims of this study were therefore to investigate the natural course of sTR progression using quantitative measurements, to assess the prognostic impact on long-term mortality, and to identify risk factors associated with progressive sTR. A total of 216 patients with heart failure with reduced ejection fraction receiving guideline-directed therapy were included in this long-term observational study. Progression of sTR was quantitatively defined as an increase of 0.2 cm Among patients with nonsevere sTR at baseline, 62 (29%) experienced sTR progression. Progressive sTR was accompanied by larger left and right atrial volumes (P = .02 and P < .02, respectively) and a higher prevalence of atrial fibrillation (P < .04). During a median follow-up period of 60 months (interquartile range, 37-60 months), 82 patients died. Progression of sTR conveyed a higher risk for long-term mortality (hazard ratio, 1.77; 95% CI, 1.1-2.83; P < .02), even after multivariate adjustment for bootstrap-selected (adjusted hazard ratio, 1.70; 95% CI, 1.06-2.74; P < .03) and clinical confounder (adjusted hazard ratio, 1.80; 95% CI, 1.07-3.05; P < .03) models. The incidence of progressive sTR despite guideline-directed therapy is associated with adverse cardiac and valvular remodeling as well as a significantly higher long-term mortality. Biatrial enlargement as well as atrial fibrillation are associated with the development of subsequent progressive sTR and may help identify patients at risk for sTR progression, potentially creating a window of opportunity for closer follow-up and newly arising minimally invasive transcatheter repair therapies.

Sections du résumé

BACKGROUND
Secondary tricuspid regurgitation (sTR) is frequent in patients with heart failure with reduced ejection fraction and is associated with adverse outcomes despite guideline-directed therapy. However, little is known about the natural course of nonsevere sTR and its relation to cardiac remodeling and outcomes. The aims of this study were therefore to investigate the natural course of sTR progression using quantitative measurements, to assess the prognostic impact on long-term mortality, and to identify risk factors associated with progressive sTR.
METHODS
A total of 216 patients with heart failure with reduced ejection fraction receiving guideline-directed therapy were included in this long-term observational study. Progression of sTR was quantitatively defined as an increase of 0.2 cm
RESULTS
Among patients with nonsevere sTR at baseline, 62 (29%) experienced sTR progression. Progressive sTR was accompanied by larger left and right atrial volumes (P = .02 and P < .02, respectively) and a higher prevalence of atrial fibrillation (P < .04). During a median follow-up period of 60 months (interquartile range, 37-60 months), 82 patients died. Progression of sTR conveyed a higher risk for long-term mortality (hazard ratio, 1.77; 95% CI, 1.1-2.83; P < .02), even after multivariate adjustment for bootstrap-selected (adjusted hazard ratio, 1.70; 95% CI, 1.06-2.74; P < .03) and clinical confounder (adjusted hazard ratio, 1.80; 95% CI, 1.07-3.05; P < .03) models.
CONCLUSIONS
The incidence of progressive sTR despite guideline-directed therapy is associated with adverse cardiac and valvular remodeling as well as a significantly higher long-term mortality. Biatrial enlargement as well as atrial fibrillation are associated with the development of subsequent progressive sTR and may help identify patients at risk for sTR progression, potentially creating a window of opportunity for closer follow-up and newly arising minimally invasive transcatheter repair therapies.

Identifiants

pubmed: 33036820
pii: S0894-7317(20)30550-2
doi: 10.1016/j.echo.2020.08.018
pii:
doi:

Types de publication

Journal Article Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

13-19

Informations de copyright

Copyright © 2020 American Society of Echocardiography. Published by Elsevier Inc. All rights reserved.

Auteurs

Georg Spinka (G)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Philipp E Bartko (PE)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Gregor Heitzinger (G)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Suriya Prausmüller (S)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Noemi Pavo (N)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Maria K Frey (MK)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Henrike Arfsten (H)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Martin Genger (M)

Division of Cardiology, Nephrology, and Intensive Care, General Hospital of Steyr, Steyr, Austria.

Christian Hengstenberg (C)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Martin Hülsmann (M)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.

Georg Goliasch (G)

Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria. Electronic address: georg.goliasch@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH